GlaxoSmithKline plc announced the appointment of six directors to the designate Board of Haleon, the new independent company to be formed following the demerger of the GSK Consumer Healthcare business, expected in July 2022. Haleon will be a new global-leading company in Consumer Health, and is strongly positioned to deliver better everyday health, sustainable above-market growth and attractive returns to shareholders. The new Board appointments follow the appointment of Sir Dave Lewis as Chair Designate in December 2021 and represent further progress to create a new, qualified Board for Haleon with the appropriate mix of skills, experience, diversity, and continuity.

The appointments include the transition of two GSK Non-Executive Directors and three new external appointees. In addition, it is also confirmed that Tobias Hestler, CFO Designate, Haleon, will join Brian McNamara, CEO Designate, Haleon, on the Board as an Executive Director. Appointments to Designate Haleon Board: Manvinder Singh (Vindi) Banga will become Senior Independent Non-Executive Director.

Vindi is currently Senior Independent Non-Executive Director of GSK. Tracy Clarke will become an independent Non-Executive Director and Chair of the Remuneration Committee; Dame Vivienne Cox will become an independent Non-Executive Director. Vivienne is currently an independent Non-Executive Director at GSK.

Deirdre Mahlan will become an independent Non-Executive Director and Chair of the Audit Risk Committee. John Young has been nominated as a Non-Executive Director by Pfizer as one of its two appointees under joint venture arrangements. John is currently a director of the GSK/Pfizer Consumer Healthcare Joint Venture company.

Tobias Hestler, CFO Designate, Haleon, will become an Executive Director.